Lightnews — Scholar-powered news

bastianengel.bsky.social @bastianengel.bsky.social · Jul 30

🔥 non-medical
🌎 planetary health is critical

Check out this video by naturalists about sustainable tourism and ocean protection on the Azores.

Scientist-led, EU-funded 🇪🇺

Happy to have joined this year. Check it out.
support them if you visit the Azores.

www.euronews.com/green/2025/0...

How Atlantic islands are proving tourism can help the ocean

From underwater archaeology to whale-watching tours led by actual scientists, Europe’s Atlantic islands demonstrate how tourism can protect rather than destroy natural and cultural heritage of the oce...

www.euronews.com

1

bastianengel.bsky.social @bastianengel.bsky.social · Jul 22

🔥 Looking for automated segmentation of liver histopathology? Don‘t look further.

Hotspot Model got you covered.

Happy to have contributed.

Great work @aleger87.bsky.social and team!

rdcu.be/ew7qh

Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model

npj Digital Medicine - Automating liver biopsy segmentation with a robust, open-source tool for pathology research: the HOTSPoT model

rdcu.be

1 2

bastianengel.bsky.social @bastianengel.bsky.social · Jul 17

🔥 Publication alert from us!

🧬 Distinct molecular profiles of AMR and TCMR after #liver #transplant
📈 AMR associates w/ high rate of graft #cirrhosis
🧪 IFN mediates TCMR, TNF mediates AMR as in other SOT

doi.org/10.1016/j.jh...

#openaccess @jhepatology.bsky.social
#liversky @easlnews.bsky.social

Redirecting

doi.org

1

bastianengel.bsky.social @bastianengel.bsky.social · Jul 17

doi.org/10.1016/j.jh...

Redirecting

doi.org

bastianengel.bsky.social @bastianengel.bsky.social · Jul 15

🔥 Publication alert from our group!

🧬 Distinct molecular profiles of AMR and TCMR after #liver #transplant
📈 AMR associates w/ high rates of graft #cirrhosis
🧪 IFN mediates TCMR and TNF mediates AMR as in other solid organs

#openaccess @jhepatology.bsky.social
#liversky @easlnews.bsky.social

1 2

Reposted

Jan Clusmann @janclusmann.bsky.social · Jun 30

Thank you for sharing! It was a pleasure working on this, together with @twittlabs.bsky.social , @jnkt.bsky.social and many others...

NEJM AI @ai.nejm.org · Jun 30

Case Study by J. Clusmann et al.: Incidental Prompt Injections on Vision–Language Models in Real-Life Histopathology nejm.ai/4mrSoEW

@janclusmann.bsky.social #AI #MedSky #DigitalHealth

Figure 1. Experimental Outline to Estimate the Impact and the Clinical Representation of Labeled Pathology Slides.

Figure 2. Incorrect Labels on Whole-Slide Images Reduce the Accuracy of Vision–Language Models Regardless of Task.

Figure 3. Misleading Watermarks Lead to a Loss in Accuracy of Tissue-of-Origin Prediction.

2 6

bastianengel.bsky.social @bastianengel.bsky.social · May 19

Whom to treat in #AIH #cirrhosis with decompensation?

💊 Steroids if:
🧠 encephalopathy equal or less than grade 2
📈 MELD-Na 28 or below

🚒If patients with AIH do not meet this criteria #transplant might be the better option.

#liversky @easlnews.bsky.social

authors.elsevier.com/c/1l6Pu5UiFS...

authors.elsevier.com

Reposted

Journal of Hepatology @jhepatology.bsky.social · May 10

🆕CPG in press❕

EASL Clinical Practice Guidelines on extrahepatic abdominal surgery in patients with cirrhosis and advanced chronic liver disease

Find it here👉https://bit.ly/3GM9EEB

#LiverSky
@easlnews.bsky.social

1 7 9

Reposted

Rob Brierley @robbrierley.bsky.social · May 8

New @thelancet.bsky.social - Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

www.thelancet.com/journals/lan...

#Liversky #Oncsky #Medsky #EASL2025

Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

Nivolumab plus ipilimumab showed a significant overall survival benefit versus lenvatinib or sorafenib and manageable safety in patients with previously untreated unresectable hepatocellular carcinoma...

www.thelancet.com

1 2

Reposted

Emma R Andersson @anderssonlab.bsky.social · May 7

Can’t wait for #EASL2025! @easlnews.bsky.social

Join Colm O’Rourke and me, on Friday for a session we’ve designed and are thrilled to chair:
“Do’s and Don’ts in Liver Transcriptomics”
Arnold Room | 3–4PM

Come for insights, tips & tricks from Neil Henderson, Johan Ankarklev, & Simon Cockell!

1 3 3

Reposted

Journal of Hepatology @jhepatology.bsky.social · Apr 3

🆕CPG❕

EASL Clinical Practice Guidelines on TIPS

✅Addresses all aspects of #TIPS in patients with #cirrhosis

Full text here: bit.ly/4hZuMUK

#LiverSky
@easlnews.bsky.social

7 13

Reposted

TherVacB Project @thervacb-eu.bsky.social · Apr 2

🤔How is #hepD treated? Why is this relevant for #hepB patients? 🇩🇪🗺️
🎞️Watch insights from #internists 🥼#HelenieKefalakes
#LisaSandmann in our fresh release youtu.be/d7dV2G6tMXA
#hepatitisawareness📺with experts answering key #HBV #HDV questions
#MHH #B_Aware #D-SOLVE #LiverHealth #LiverSky #HepSky

How is hepatitis D treated?

YouTube video by TherVacB - Awareness & Insights on Hepatitis B

youtu.be

1 3 2

Reposted

Zunamys Carrero @zcarrero-katherlab.bsky.social · Mar 31

✮ Kather Lab is hiring PostDocs & Software Engineers!

☞ Strong Python & PyTorch skills, GitHub experience, and interest in LLMs & computational pathology required.   

Apply here╰( ͡° ͜ʖ ͡° )つ──☆*・ﾟ: bit.ly/42nY62u

2 10

Reposted

Jakob Nikolas Kather @jnkt.bsky.social · Mar 27

Happy to share our latest paper in @ai.nejm.org, led by Isabella Wiest: "Deidentifying Medical Documents with Local, Privacy-Preserving Large Language Models: The LLM-Anonymizer" ai.nejm.org/doi/full/10....
You can use our open source tool with local LLMs to robustly de-identify medical documents.

1 5 9

Reposted

Elliot Tapper @ebtapper.bsky.social · Mar 4

Spicy!

Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors

@juancarlosqvelez.bsky.social

doi.org/10.1016/j.ek...
#nephsky #liversky

2 9 26

bastianengel.bsky.social @bastianengel.bsky.social · Feb 21

Find the latest evidence on #autoimmune #liver diseases (in German, but #AI will help to translate) in which we summarize the latest evidence, finally on the highest level achievable for guidelines.

This highlights the progress in the #AILD field in the last years.

www.dgvs.de/leitlinien/l...

Seltene Lebererkrankungen (LeiSe LebEr) - DGVS - Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten

www.dgvs.de

1

bastianengel.bsky.social @bastianengel.bsky.social · Feb 20

@joostphdrenth.bsky.social @easlnews.bsky.social @aleger87.bsky.social #LiverSky

bastianengel.bsky.social @bastianengel.bsky.social · Feb 20

Fresh from #Hepatology, cross-sectional multicenter study on Quality of Life in #AIH.

👍 882 patients, 178 controls across Europe #ERN
👎 QoL impaired mainly by physical complaints
📈 QoL correlated w/ depression/anxiety
💊 remission associated w/ improved symptoms

doi.org/10.1097/HEP.0000000000001271

ted outcome measures. Methods: Adult AIH patients diagnosed at 12 European centers were enrolled in this prospective, cross-sectional study from July 2020-June 2023. HRQoL was assessed using the Ph...

doi.org

1

Reposted

EASL @easlnews.bsky.social · Feb 19

In today's #readoftheweek📚 learn about the ALNE model and how it generates quantitative and accurate differential diagnosis between cases with AIH or PBC.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

@jhepatology.bsky.social #LiverSky

4 7

bastianengel.bsky.social @bastianengel.bsky.social · Feb 20

Happy to have contributed to this project led by @aleger87.bsky.social

🤖 ML-based detection of AIH and PBC from H&E stained slides
💥 solid performance with heterogenous staining/scanning
😳 no annotation needed

More to come and looking forward to it! @jnkt.bsky.social #liversky

EASL @easlnews.bsky.social · Feb 19

In today's #readoftheweek📚 learn about the ALNE model and how it generates quantitative and accurate differential diagnosis between cases with AIH or PBC.

Read here this JHEP Reports article: www.jhep-reports.eu/article/S258...

@jhepatology.bsky.social #LiverSky

1 4

bastianengel.bsky.social @bastianengel.bsky.social · Feb 18

@jhep-reports.bsky.social @easlnews.bsky.social @jhepatology.bsky.social

bastianengel.bsky.social @bastianengel.bsky.social · Feb 18

🔥 off the press.
Multicenter study using proteomic signatures to identify biomarker candidates in acute liver failure led by Pavel Strnad from Aachen.

🏨 disriminate APAP from non-APAP
📉 predict transplant-free survival from 🩸
🧮 outperform MELD and AFLSG-PI

Great work 👏 doi.org/10.1016/j.jh...

Redirecting

doi.org

1

Reposted

Jan Clusmann @janclusmann.bsky.social · Feb 18

The autoimmune hepatitis field is quite unique in the way clinicians and researchers on AIH are connected personally worldwide. Optimal starting point for generalizable prediction algorithms ...

bastianengel.bsky.social @bastianengel.bsky.social · Feb 18

@aleger87.bsky.social @janclusmann.bsky.social @jhep-reports.bsky.social @joostphdrenth.bsky.social

1 1

bastianengel.bsky.social @bastianengel.bsky.social · Feb 18

@aleger87.bsky.social @janclusmann.bsky.social @jhep-reports.bsky.social @joostphdrenth.bsky.social

bastianengel.bsky.social @bastianengel.bsky.social · Feb 18

@easlnews.bsky.social @jhepatology.bsky.social

1